Prof Axel Hauschild speaks to ecancer at ASCO 2024 about results from the phase III PIVOTAL study which evaluated neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.

Patients were 1:1 randomly assigned to receive up to 4 weekly intratumoral injections of daromun followed by surgery or surgery alone within 4 weeks from randomisation.

The analysis of the primary efficacy endpoint RFS and of secondary endpoints DMFS, pCR and safety show that neoadjuvant daromun is an effective and safe therapeutic option for resectable, locally advanced melanoma patients.